Camurus Q2 FY26 operating result rises to MSEK 293; revenue increases 4% to MSEK 702

PUBT · 2d ago
Camurus Q2 FY26 operating result rises to MSEK 293; revenue increases 4% to MSEK 702
  • Camurus posted Q2 revenue up 4% to MSEK 702; operating result edged up to MSEK 293.
  • Product sales rose 13% to MSEK 528; Brixadi royalty revenue climbed 42% to MSEK 127.
  • Milestone payments fell to MSEK 46; cash position increased to BNSEK 4.1 at quarter-end.
  • FDA issued a Complete Response Letter for the CAM2029 NDA for acromegaly in the US; Lilly exercised its amylin option under the collaboration.
  • CEO Fredrik Tiberg cited renewed Buvidal growth, continued US Brixadi royalty growth; 2026 financial outlook reiterated.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camurus AB published the original content used to generate this news brief via Cision (Ref. ID: 202607150100BITN____UKPR__EN_20260714-BIT-8901-0) on July 15, 2026, and is solely responsible for the information contained therein.